Tiny RXi bags an op­tion to buy CAR-T fledg­ling Mir­Im­mune

Eigh­teen months af­ter Mir­Im­mune grabbed a li­cense to RXi’s $RXII RNA tech for use in de­vel­op­ing new cell ther­a­pies, the tiny moth­er ship — with a mar­ket cap of on­ly $11 mil­lion af­ter a steady fade of its stock price — is now look­ing to reel back the whole ef­fort un­der a buy­out op­tion.

Based in Marl­bor­ough, MA with a group of co-founders that in­cludes the for­mer CEO of Sepra­cor, Tim Bar­berich, the low-pro­file Mir­Im­mune went to RXi last March to gain a li­cense to a tech that could be used to de­vel­op new cell im­munother­a­pies for can­cer — a hot top­ic in the biotech world. Ini­tial­ly, RXi had re­served an op­tion for a chunk of Mir­Im­mune.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER